Cargando…

Carboplatin- and cisplatin-induced potentiation of moderate-dose radiation cytotoxicity in human lung cancer cell lines.

The interaction between moderate-dose radiation and cisplatin or carboplatin was studied in a cisplatin-sensitive (GLC4) and -resistant (GLC4-CDDP) human small-cell lung cancer cell line. Cellular toxicity was analysed under oxic conditions with the microculture tetrazolium assay. For the platinum a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Groen, H. J., Sleijfer, S., Meijer, C., Kampinga, H. H., Konings, A. W., De Vries, E. G., Mulder, N. H.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1995
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2034078/ https://www.ncbi.nlm.nih.gov/pubmed/8519652

Ejemplares similares

Acute and cumulative effects of carboplatin on renal function.
por: Sleijfer, D. T., et al.
Publicado: (1989)

Pharmacokinetics of carboplatin at a dose of 750 mg m-2 divided over three consecutive days.
por: Mulder, P. O., et al.
Publicado: (1990)

Cisplatin sensitivity and thermochemosensitisation in thermotolerant cDDP-sensitive and -resistant cell lines.
por: Hettinga, J. V., et al.
Publicado: (1995)

Mechanism of hyperthermic potentiation of cisplatin action in cisplatin-sensitive and -resistant tumour cells.
por: Hettinga, J. V., et al.
Publicado: (1997)

Treatment of advanced seminoma with cyclophosphamide, vincristine and carboplatin on an outpatient basis.
por: Sleijfer, S., et al.
Publicado: (1996)

Cisplatin in breast cancer.
por: Willemse, P., et al.
Publicado: (1993)

The role of glutathione in resistance to cisplatin in a human small cell lung cancer cell line.
por: Meijer, C., et al.
Publicado: (1990)

Application of prolonged microdialysis sampling in carboplatin-treated cancer patients
por: Konings, Inge R. H. M., et al.
Publicado: (2008)

Effects of Buthionine Sulfoximine Treatment on Cellular Glutathione Levels and Cytotoxicities of Cisplatin, Carboplatin and Radiation in Human Stomach and Ovarian Cancer Cell Lines(*): – Glutathione, Buthionine Sulfoximine, Cytotoxicity –
por: Lee, Kyung Shik, et al.
Publicado: (1992)

Continuous carboplatin infusion during 6 weeks' radiotherapy in locally inoperable non-small-cell lung cancer: a phase I and pharmacokinetic study.
por: Groen, H. J., et al.
Publicado: (1995)

Paclitaxel-etoposide-carboplatin/cisplatin versus etoposide-carboplatin/cisplatin as first-line treatment for combined small-cell lung cancer: a retrospective analysis of 62 cases
por: Li, Yue-Ya, et al.
Publicado: (2015)

Cisplatin/carboplatin cross-resistance in ovarian cancer.
por: Gore, M. E., et al.
Publicado: (1989)

Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer
por: Sculier, J-P, et al.
Publicado: (2000)

Comparative evaluation of cisplatin and carboplatin sensitivity in endometrial adenocarcinoma cell lines.
por: Rantanen, V., et al.
Publicado: (1994)

Early to late sparing of radiation damage to the parotid gland by adrenergic and muscarinic receptor agonists
por: Coppes, R P, et al.
Publicado: (2001)

Cellular basis for differential sensitivity to cisplatin in human germ cell tumour and colon carcinoma cell lines.
por: Sark, M. W., et al.
Publicado: (1995)

Haematological toxicity of carboplatin and cisplatin combined with whole body hyperthermia in rats.
por: Ohno, S., et al.
Publicado: (1993)

Risk of thromboembolism in cisplatin versus carboplatin-treated patients with lung cancer
por: Kim, Eric S., et al.
Publicado: (2017)

Comparison of Carboplatin With Cisplatin in Small Cell Lung Cancer in US Veterans
por: Azar, Ibrahim, et al.
Publicado: (2022)

Comparison of full-dose gemcitabine/cisplatin, dose-reduced gemcitabine/cisplatin, and gemcitabine/carboplatin in real-world patients with advanced urothelial carcinoma
por: Sugimoto, Kazuma, et al.
Publicado: (2022)

The formation and removal of cisplatin (CDDP) induced DNA adducts in a CDDP sensitive and resistant human small cell lung carcinoma (HSCLC) cell line.
por: Hospers, G. A., et al.
Publicado: (1990)

LEVELS OF GLUTATHIONES TRANSFERASE π mRNA IN HUMAN LUNG CANCER CELL LINES CORRELATE WITH THE RESISTANCE TO CISPLATIN AND CARBOPLATIN
por: Nakagawa, Kazuhiko, et al.
Publicado: (1988)

Carboplatin versus cisplatin in combination with etoposide in the first-line treatment of small cell lung cancer: a pooled analysis
por: Jiang, Shiyu, et al.
Publicado: (2021)

Response of peritoneal solid tumours after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin.
por: Los, G., et al.
Publicado: (1994)

First-line gemcitabine with cisplatin or epirubicin in advanced non-small-cell lung cancer: a phase III trial
por: Wachters, F M, et al.
Publicado: (2003)

Amrubicin: potential in combination with cisplatin or carboplatin to treat small-cell lung cancer
por: Ding, Qian, et al.
Publicado: (2013)

Correction: Risk of thromboembolism in cisplatin versus carboplatin-treated patients with lung cancer
Publicado: (2018)

Oxaliplatin-Based Doublets Versus Cisplatin or Carboplatin-Based Doublets in the First-Line Treatment of Advanced Nonsmall Cell Lung Cancer
por: Yu, Jing, et al.
Publicado: (2015)

Cisplatin or carboplatin for advanced non-small cell lung cancer: does it really matter?
por: Kesireddy, Meghana, et al.
Publicado: (2021)

Immunocytochemical analysis of cisplatin-induced platinum-DNA adducts with double-fluorescence video microscopy.
por: Meijer, C., et al.
Publicado: (1997)

Whole body hyperthermia and carboplatin: cytotoxicity for murine leukaemia and normal marrow.
por: Tapazoglou, E., et al.
Publicado: (1991)

Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702
por: Okamoto, H, et al.
Publicado: (2007)

Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines.
por: Zangemeister-Wittke, U., et al.
Publicado: (1998)

FTIR Biospectroscopy Investigation on Cisplatin Cytotoxicity in Three Pairs of Sensitive and Resistant Cell Line
por: Farhadi, Ensieh, et al.
Publicado: (2016)

Comparison of Myelotoxicity and Nephrotoxicity Between Daily Low-Dose Cisplatin With Concurrent Radiation and Cyclic High-Dose Cisplatin in Non-Small Cell Lung Cancer Patients
por: Zazuli, Zulfan, et al.
Publicado: (2020)

Hymenialdisine is Cytotoxic Against Cisplatin-Sensitive but Not Against Cisplatin-Resistant Cell Lines
por: Abdullah, Nada, et al.
Publicado: (2021)

Additive and supra-additive cytotoxicity of cisplatin-taxane combinations in ovarian carcinoma cell lines
por: Engblom, P, et al.
Publicado: (1999)

Adjustment of creatinine clearance improves accuracy of Calvert's formula for carboplatin dosing.
por: Ando, Y., et al.
Publicado: (1997)

Evaluation of calculating carboplatin dosage in carboplatin–pemetrexed therapy as the first‐line therapy for Chinese patients with advanced lung adenocarcinoma
por: Zhu, Yixiang, et al.
Publicado: (2018)

Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage III non–small cell lung cancer
por: Liew, Mun Sem, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_v19pl0tna2d1sqe48fufsliisq